Maryland-based, woman-owned biotech company providing hospitals with an autotransfusion device to address the global blood shortage

COLUMBIA, Md. (October 23, 2023) – TEDCO, Maryland’s economic engine for technology companies, announced a recent Inclusion Fund investment of $100,000 into Sisu Global Health, a company that is providing hospitals with an autotransfusion device to replace or augment donor blood in emergency situations.

Sisu Global Health, based in Baltimore, Md., has created an autotransfusion device, Hemafuse; the device provides surgical patients access to fresh, whole blood by capturing it from internal bleeding and giving it back to them immediately in the same surgery. The patented Hemafuse System can operate anywhere there is a surgeon (regardless of infrastructure), making it well suited for military and emerging markets, with applications in the U.S., Sisu Global is bringing Hemafuse to the global market after clinical success in Ghana, Kenya, Tanzania and Ukraine.

FDA Clears Rise Therapeutics' IND Application to Initiate a Phase 1 Clinical Study of Its Novel Oral Immunotherapy for the Treatment of Rheumatoid Arthritis

ROCKVILLE, Md., Oct. 19, 2023 /PRNewswire/ -- Rise Therapeutics a biotechnology company engaged in developing novel oral immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application to proceed with a rheumatoid arthritis Phase 1 clinical trial for its program candidate, R-2487. This is Rise Therapeutics' second clinical program developed using synthetic biology and its proprietary oral biologics delivery platform.

RICHMOND, Va.--(BUSINESS WIRE)-- Qnovia, Inc., a pharma company developing inhaled therapeutics across a variety of indication areas, today announced it has entered into a drug development collaboration with the University of Virginia (UVA) to advance novel inhaled-drug candidates for treating bacterial infections in the lungs. Qnovia will work with UVA School of Medicine investigators Dr. Molly Hughes and Dr. Matthew Crawford to combine Qnovia’s RespiRx^TM inhaled drug delivery platform and UVA’s proprietary portfolio of antimicrobial peptides to kill antibiotic-resistant and biodefense bacteria that can cause life-threatening infections. As a result of this agreement, Qnovia will add two new assets to its development pipeline: QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection for individuals exposed to the biodefense agent B. anthracis, the causative agent of anthrax.

With an increasing number of U.S. biopharmaceutical firms feeling the financial constraints imposed by the Inflation Reduction Act (IRA) and subsequently shutting down or suspending their research programs in the rare disease domain, hundreds of millions of patients in both the U.S. and India face the grim prospect of not receiving a breakthrough treatment for their condition within their lifetimes. IndoUSrare, a US-based nonprofit committed to stanching rare diseases, launches the inaugural Bridging RARE conference to forge a path for affordable clinical innovation via strengthened Indo-US collaborations and more inclusive clinical trials for minimizing the devastating health consequences arising from this policy shift.

(HERNDON, Va.) October 10, 2023: Rare diseases, as defined by the World Health Organization (WHO), refer to some 10,867 medically significant conditions, each with a prevalence of one or less per 1,000 individuals. With only about 8% of them being treatable,¹ rare diseases include congenital malformations, autoimmune disorders, lysosomal storage disorders, thalassemia, muscular dystrophies, and infrequent forms of cancer and infections. Despite substantial progress during the 40 years since the enactment of the Orphan Drug Act of 1983, which incentivized the U.S. private sector to develop 1,100 FDA-approved orphan treatments,² the global thrust against rare diseases is on the verge of losing steam.

REGISTER NOW